Trial Profile

The Effect of Omega-3 Fatty Acids (Omacor) on the Response Rate to Antiviral Therapy in Patients With Chronic Hepatitis C Infection.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 11 Jan 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omega-3-acid ethyl esters (Primary) ; Interferon
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

07 Aug 2012 Actual end date (1 Aug 2012) added as reported by ClincialTrials.gov.
08 Jul 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
13 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com